Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells

Highlights • Cytokine release syndrome (CRS) is a fatal complication in CAR-T cell therapy. • CRS correlates with CAR structures, underlying diseases and cytokine gene polymorphisms. • CRS may be reduced by dose-escalation scheme, designing safer CARs and short-lived CAR-T cell infusion. • CRS can b...

Full description

Saved in:
Bibliographic Details
Published inCancer letters Vol. 343; no. 2; pp. 172 - 178
Main Authors Xu, Xiao-Jun, Tang, Yong-Min
Format Journal Article
LanguageEnglish
Published Ireland Elsevier Ireland Ltd 28.02.2014
Elsevier Limited
Subjects
Adverse event
Cancer
Cardiac arrhythmia
Chemokines
Chimeric antigen receptor
Clinical trials
Cytokine release syndrome
Cytokines
Cytokines - metabolism
Fever
Headaches
Hematology, Oncology and Palliative Medicine
Humans
Immune system
Immunotherapy
Liver
Lymphocytes
Nausea
Neoplasms - immunology
Neoplasms - therapy
Proteins
Receptors, Antigen, T-Cell - therapeutic use
Recombinant Fusion Proteins - therapeutic use
Respiratory distress syndrome
Safety
Syndrome
Adverse event
Cytokine release syndrome
Safety
Chimeric antigen receptor
Cancer
Online AccessGet full text

Cover

More Information
Summary:Highlights • Cytokine release syndrome (CRS) is a fatal complication in CAR-T cell therapy. • CRS correlates with CAR structures, underlying diseases and cytokine gene polymorphisms. • CRS may be reduced by dose-escalation scheme, designing safer CARs and short-lived CAR-T cell infusion. • CRS can be controlled by cytokine-directed therapy using steroid and antagonists of cytokines.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2013.10.004